Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$57.31 USD

57.31
4,084,323

-0.42 (-0.73%)

Updated Oct 15, 2024 04:00 PM ET

After-Market: $57.29 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mark Vickery headshot

New Stimulus, Moderna & Durable Goods Kick Off Monday

We have $1 trillion in stimulus expected from the congressional GOP today and a phase 3 trial beginning for Moderna's (MRNA) COVID-19 vaccine candidate.

Economic Data Deluge

Economic Data Deluge

Sanghamitra Saha headshot

3 Top Sector ETFs to Start Q3 With More Room for Growth

We entered the third quarter some weeks ago with no abatement (rather surges) on the virus front and several U.S. states reversing the course of economic reopening.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain on Coronavirus Vaccine Progress

The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.

The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax

The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax

Kaibalya Pravo Dey headshot

EU Stimulus, Vaccine Hopes Aid Oil Price, Upstream Stocks Rise

Significant gains in crude prices are likely to provide a profit-boosting opportunity to exploration and production companies.

3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data

Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.

Sweta Killa headshot

Top and Flop ETFs to Start Third Quarter

We have highlighted ETFs from the best and worst zones to start the third quarter.

David Borun headshot

Quiet Week Could be the Calm Before the Storm

A busy week of earnings reports and Congressional stimulus talks has t

Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress

Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.

Moderna (MRNA) Gains As Market Dips: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $81.81, marking a +1.98% move from the previous day.

Moleculin Surges on Manufacturing Deal for Coronavirus Therapy

Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.

Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Sweta Killa headshot

Travel & Leisure ETFs Jump on Vaccine Optimism

Investors rushed to the beaten-down sectors, including cruise lines, airlines, hotel and casino operators, and travel and entertainment-booking companies.

Stock Market News for Jul 16, 2020

Benchmarks edged up on Wednesday as investors cheered promising data for a potential COVID-19 vaccine and few better-than-expected quarterly earnings reports.

The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi

The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi

Nilanjan Banerjee headshot

Coronavirus Vaccine Hopes Buoy Market: 4 Stocks to Tap the Rally

With the doses of good news aiding the stock market rally, it will be wise for the investors to invest in growth stocks.

Moderna (MRNA) in Focus: Stock Moves 6.9% Higher

Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Sanghamitra Saha headshot

Vaccine Hopes Boost These Sectors & ETFs

Vaccine hopes and some upbeat banking earnings have boosted the risk-on sentiments in Wall Street.

Sweta Jaiswal, FRM headshot

Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

Sweta Killa headshot

How to Tap Red-Hot Moderna Stock With ETFs

Moderna shares have surged more than 280% so far this year on the positive development of coronavirus vaccine.

Q2 Earnings in Focus

Q2 Earnings in Focus

Mark Vickery headshot

Goldman Boosts Dow with Best Quarter in Years

Goldman simply blew the doors off Q2 expectations, posting $6.26 per share on $13.3 billion in quarterly revenues which compare very favorably with the $3.97 per share and $10.07 billion in the Zacks consensus.

Company News for Jul 15, 2020

Companies in the news are: WIT, FRC, FAST, MRNA

Moderna Rallies on Encouraging Coronavirus Vaccine Study Data

Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.